▶주메뉴 바로가기
▶본문 바로가기
[THE INVESTOR] SK Biopharmaceuticals said on Oct. 15 it has developed a drug design platform based on artificial intelligence which will help it reduce research costs while speeding up the developme...
[THE INVESTOR] An affiliate of Korean biopharmaceutical firm Celltrion said on Oct. 15 that the market share of its biosimilar drug Truxima surpassed 30 percent in Europe during the second quarter. ...
[THE INVESTOR] Sugentech said on Oct. 11 it plans to launch a non-invasive testing system that will enable the early detection of Alzheimer’s disease using snot by 2022. The Korean biotech firm has...
[THE INVESTOR] The US FDA’s advisory committee has approved advancing the application of Celltrion's CT-P10, a copy version to Roche’s blockbuster cancer drug Rituxan, the Korean biopharmaceutical...
[THE INVESTOR] DAYLI Partners CEO Lee Seung-ho reckons a sea change in the local biotechnology industry and is gearing up to reap huge profits from the fast-growing segment. “I haven’t seen this ki...
[THE INVESTOR] Merck, a global health care company, has won a US$117 million contract to supply the biosimilar Renflexis, developed by Samsung Bioepis, to the US Department of Veterans Affairs, indu...
[THE INVESTOR] Korean drug firm Chong Kun Dang Pharmaceutical said on Oct. 5 that it sought approval for sales of its anemia biosimilar in Japan from health authorities there earlier this week. ...
[THE INVESTOR] Korean pharmaceutical firm Dong-A ST said on Oct. 1 its co-developer Sanwa Kagaku Kenkyusho has sought approval from the Japanese health regulator for its biosimilar version of Amgen’...
[THE INVESTOR] Samsung BioLogics , Korea’s biopharmaceutical contract development and manufacturing organization said on Oct. 1 that its third plant -- the world’s largest single bio manufacturing ...
[THE INVESTOR] Samsung Bioepis said on Sept. 27 that the US Food and Drug Administration has accepted its application to review SB5, its biosimilar candidate referencing US drug maker AbbVie’s Humir...
[THE INVESTOR] The financial regulator said on Sept. 19 it will allow biotechnology and pharmaceutical firms to voluntarily restate accounting errors amid a lack of clear supervisory rules on the in...
[THE INVESTOR] Celltrion said Sept. 16 that the US Food and Drug Administration has given its OK to the Korean biopharmaceutical firm’s manufacturing facility after re-inspection, clearing a year-l...
[THE INVESTOR] Korean pharmaceutical and bio companies have seen their share prices surge about 20 percent recently on eased concerns over accounting regulations and other positive factors, data sho...
[THE INVESTOR] Olix , Korea’s RNA-interference drug developer, said on Sept. 17 it has tapped former Boston Biomedical executive Wei Li to lead its new entity in the US. Li has been appointed as C...
[THE INVESTOR] Allergan has confirmed it will soon begin pivotal phase 3 clinical trials of a liquid-type botulinum toxin it licensed from Korean biotech Medytox with hopes to get US marketing app...
SKINFOOD to close outlets in E-mart, E-Land Retail
Chinese crypto exchange BTCC to launch service in Korea
Bithumb’s new chief hints at Hong Kong launch
Samsung announces new automotive chip brands
Google to set up data center in Korea next year
Samsung Galaxy Note 10 to beat Apple’s iPhone XS in screen size
SKT, Samsung complete first 5G call
CJ CGV’s Vietnam unit to slow down IPO process
October 16, 2018
